Kremer, Andreas E.

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: Interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Younossi, Z. M., Ratziu, V., Loomba, R., Rinella, M., Anstee, Q. M., Goodman, Z., Bedossa, P., Geier, A., Beckebaum, S., Newsome, P. N., et al. (2019) · The Lancet

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 1,277

Lysophosphatidic Acid Is a Potential Mediator of Cholestatic Pruritus

Kremer, A. E., Martens, J. J. W. W., Kulik, W., Ruëff, F., Kuiper, E. M. M., van Buuren, H. R., van Erpecum, K. J., Kondrackiene, J., Prieto, J., Rust, C., et al. (2010) · Gastroenterology

Dermatology and Skin DiseasesLiver Diseases and Immunity

Cited by 410

The Biliary HCO3 − Umbrella: A Unifying Hypothesis on Pathogenetic and Therapeutic Aspects of Fibrosing Cholangiopathies

Beuers, U., Hohenester, S., de Buy Wenniger, L. J. M., Kremer, A. E., Jansen, P. L. M., & Elferink, R. P. J. O. (2010) · Hepatology

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 351

Serum autotaxin is increased in pruritus of cholestasis, but not of other origin and responds to therapeutic interventions

Kremer, A. E., van Dijk, R., Leckie, P., Schaap, F. G., Kuiper, E. M. M., Mettang, T., Reiners, K. S., Raap, U., van Buuren, H. R., van Erpecum, K. J., et al. (2012) · Hepatology

Liver Diseases and ImmunityDermatology and Skin Diseases

Cited by 291

A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis

Hirschfield, G. M., Bowlus, C. L., Mayo, M. J., Kremer, A. E., Vierling, J. M., Kowdley, K. V., Levy, C., Villamil, A., Ladrón de Guevara Cetina, A. L., Janczewska, E., et al. (2024) · New England Journal of Medicine

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 286

Pruritus in cholestasis: facts and fiction

Beuers, U., Kremer, A. E., Bolier, R., & Elferink, R. P. J. O. (2014) · Hepatology

Liver Diseases and ImmunityDermatology and Skin Diseases

Cited by 225

Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study

Jones, D., Boudes, P. F., Swain, M. G., Bowlus, C. L., Galambos, M. R., Bacon, B. R., Doerffel, Y., Gitlin, N., Gordon, S. C., Odin, J. A., et al. (2017) · The Lancet Gastroenterology & Hepatology

Liver Diseases and ImmunityPeroxisome Proliferator-Activated Receptors

Cited by 191

PU.1 controls fibroblast polarization and tissue fibrosis

Wohlfahrt, T., Rauber, S., Uebe, S., Luber, M., Soare, A., Ekici, A., Weber, S., Matei, A.-E., Chen, C.-W., Maier, C., et al. (2019) · Nature

TGF-β signaling in diseasesLiver physiology and pathology

Cited by 187

The pseudokinase MLKL mediates programmed hepatocellular necrosis independently of RIPK3 during hepatitis

Günther, C., He, G.-W., Kremer, A. E., Murphy, J. M., Petrie, E. J., Amann, K., Vandenabeele, P., Linkermann, A., Poremba, C., Schleicher, U., et al. (2016) · Journal of Clinical Investigation

Cell death mechanisms and regulationLiver Diseases and Immunity

Cited by 157

Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis

Corpechot, C., Carrat, F., Gaouar, F., Chau, F., Hirschfield, G., Gulamhusein, A., Montano-Loza, A. J., Lytvyak, E., Schramm, C., Pares, A., et al. (2022) · Journal of Hepatology

Liver Diseases and ImmunityLiver Disease Diagnosis and Treatment

Cited by 128

Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study

Hirschfield, G. M., Shiffman, M. L., Gulamhusein, A., Kowdley, K. V., Vierling, J. M., Levy, C., Kremer, A. E., Zigmond, E., Andreone, P., Gordon, S. C., et al. (2023) · Hepatology

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 127

Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases

Lynch, K. D., Chapman, R. W., Keshav, S., Montano-Loza, A. J., Mason, A. L., Kremer, A. E., Vetter, M., de Krijger, M., Ponsioen, C. Y., Trivedi, P., et al. (2020) · Clinical Gastroenterology and Hepatology

Liver Diseases and ImmunityInflammatory Bowel Disease

Cited by 105

GLIMMER: A Randomized Phase 2b Dose-Ranging Trial of Linerixibat in Primary Biliary Cholangitis Patients With Pruritus

Levy, C., Kendrick, S., Bowlus, C. L., Tanaka, A., Jones, D., Kremer, A. E., Mayo, M. J., Haque, N., von Maltzahn, R., Allinder, M., et al. (2023) · Clinical Gastroenterology and Hepatology

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 101

Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?

Corpechot, C., Lemoinne, S., Soret, P.-A., Hansen, B., Hirschfield, G., Gulamhusein, A., Montano-Loza, A. J., Lytvyak, E., Pares, A., Olivas, I., et al. (2024) · Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 94

Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial

Traussnigg, S., Schattenberg, J. M., Demir, M., Wiegand, J., Geier, A., Teuber, G., Hofmann, W. P., Kremer, A. E., Spreda, F., Kluwe, J., et al. (2019) · The Lancet Gastroenterology & Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 88

Open‐label, clinical trial extension: Two‐year safety and efficacy results of seladelpar in patients with primary biliary cholangitis

Mayo, M. J., Vierling, J. M., Bowlus, C. L., Levy, C., Hirschfield, G. M., Neff, G. W., Galambos, M. R., Gordon, S. C., Borg, B. B., Harrison, S. A., et al. (2024) · Alimentary Pharmacology & Therapeutics

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 39

Primary biliary cholangitis drug evaluation and regulatory approval: Where do we go from here?

Jones, D. E. J., Beuers, U., Bonder, A., Carbone, M., Culver, E., Dyson, J., Gish, R. G., Hansen, B. E., Hirschfield, G., Jones, R., et al. (2024) · Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 38

Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial

Hirschfield, G. M., Bowlus, C. L., Jones, D. E. J., Kremer, A. E., Mayo, M. J., Tanaka, A., Andreone, P., Jia, J., Jin, Q., Macías-Rodríguez, R. U., et al. (2026) · The Lancet Gastroenterology & Hepatology

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 34

Long-Term Efficacy and Safety of Selective PPARδ Agonist Seladelpar in Primary Biliary Cholangitis: ASSURE Interim Study Results

Levy, C., Trivedi, P. J., Kowdley, K. V., Gordon, S. C., Bowlus, C. L., Londoño, M. C., Hirschfield, G. M., Gulamhusein, A., Lawitz, E. J., Vierling, J. M., et al. (2026) · American Journal of Gastroenterology

Liver Diseases and ImmunityPeroxisome Proliferator-Activated Receptors

Cited by 20

Advancing care in primary biliary cholangitis: emerging insights and novel therapies

Vögelin, M., & Kremer, A. E. (2025) · Expert Opinion on Pharmacotherapy

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 5